A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

(2016) Sofie Wilgenhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

(2015) Kalijn F Bol et al.   OncoImmunology

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases

(2014) Sofie Wilgenhof et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells

(2014) J. Carrasco et al.   JOURNAL OF IMMUNOLOGY

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

(2013) S. Wilgenhof et al.   ANNALS OF ONCOLOGY

Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients

(2012) Sergiusz Markowicz et al.   MEDICAL ONCOLOGY

Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients

(2012) An MT Van Nuffel et al.   MOLECULAR THERAPY

Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient

(2011) An M. T. Van Nuffel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma

(2011) Sofie Wilgenhof et al.   JOURNAL OF IMMUNOTHERAPY

Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases

(2010) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines

(2010) Emanuela Romano et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients

(2009) A. Bonehill et al.   CLINICAL CANCER RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA

(2008) Aude Bonehill et al.   MOLECULAR THERAPY